Monday, May 11, 2015
New CPIC Guideline: CYP2D6 and CYP2C19 and Selective Serotonin Reuptake Inhibitors
Guidelines by the Clinical Pharmacogenetics Implementation Consortium (CPIC) regarding the use of pharmacogenetic tests for CYP2D6 and CYP2C19 in dosing selective serotonin reuptake inhibitors (SSRIs) have been accepted for publication in Clinical Pharmacology and Therapeutics.
SSRIs are used as a first line treatment for major depressive and anxiety disorders, and may be used to treat other psychiatric conditions. Paroxetine and fluvoxamine are extensively metabolized by CYP2D6 and variations in CYP2D6 activity may result in lower or greater exposure to these drugs. While variations in CYP2C19 activity may result in altered drug exposure for citalopram, escitalopram, and sertraline.
For therapeutic recommendations and further details see these guidelines for paroxetine, fluvoxamine, citalopram, escitalopram, and sertraline on PharmGKB.